ST. HELIER, JERSEY, 9 March 2016 – Novocure (NASDAQ: NVCR) announced today that a computational study analyzing the effect of transducer layout on Tumor Treating Fields, or TTFields, distribution has been published in the International Journal of Radiation Oncology • Biology • Physics, also known as the Red Journal. The study results suggest that customizing transducer array layouts based on tumor locations can significantly increase field strength within tumors.
The anti-mitotic effect of TTFields is dose-dependent starting at an electric field strength of 1 V/cm and increasing with increasing field intensity. Consistent with prior research, the average electric field induced in the published model exceeded the therapeutic threshold of 1 V/cm in all tumors. Field strength within a tumor did not correlate with its size or shape but was dependent on tumor location. Field strength always increased when the array layout was adapted according to the anatomic location of the tumor.
The full study can be accessed here.
Ad Statistics
Times Displayed: 112448
Times Visited: 6718 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
Novocure offers a transducer array layout system, the NovoTAL System, allowing certified Optune prescribers to optimize TTFields therapy for each glioblastoma, or GBM, patient. The personalized transducer array layout maximizes the intensity of TTFields within a patient’s tumor based on morphological measurements of the head, tumor size and location. With the NovoTAL system, healthcare providers who have been trained and certified can generate transducer array layout maps for their Optune patients as an office-based procedure.
About Tumor Treating Fields Therapy
Tumor Treating Fields (TTFields) therapy is delivered by a portable, non-invasive medical device designed for continuous use by patients. In vitro and in vivo studies have shown that TTFields therapy slows and reverses tumor growth by inhibiting mitosis, the process by which cells divide and replicate. TTFields therapy creates low intensity, alternating electric fields within a tumor that exert physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death.
Approved Indications
In the United States, Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).
In the United States, Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy.
